What is the ranking of all statins by efficacy and effectiveness in lowering LDL cholesterol and triglycerides?

Statin Ranking by LDL-Cholesterol and Triglyceride Lowering Efficacy

Based on the 2018 AHA/ACC Cholesterol Guidelines, rosuvastatin and atorvastatin at maximum doses are the most potent statins for LDL-cholesterol reduction (≥50% reduction), with rosuvastatin demonstrating superior efficacy at equivalent high-intensity dosing. 1

LDL-Cholesterol Lowering: Ranked by Intensity Category

The ACC/AHA guidelines stratify statins into three evidence-based intensity categories based on their LDL-C lowering capacity 1, 2:

High-Intensity Statins (≥50% LDL-C Reduction)

1. Rosuvastatin 20-40 mg - Most potent overall (SUCRA ranking 93.1% for LDL-C lowering) 3
2. Atorvastatin 40-80 mg - Second most potent, though rosuvastatin 40 mg demonstrates statistically superior LDL-C reduction compared to atorvastatin 80 mg 4

These are the only two statins capable of achieving ≥50% LDL-C reduction and are derived from the VOYAGER database meta-analysis 1.

Moderate-Intensity Statins (30-49% LDL-C Reduction)

1. Rosuvastatin 5-10 mg
2. Atorvastatin 10-20 mg
3. Simvastatin 20-40 mg (Note: FDA warns against 80 mg due to myopathy risk) 1, 5
4. Pravastatin 40-80 mg

Low-Intensity Statins (<30% LDL-C Reduction)

1. Pitavastatin 1-4 mg
2. Lovastatin 20-40 mg
3. Simvastatin 10 mg
4. Pravastatin 10-20 mg
5. Fluvastatin 20-80 mg (including extended-release formulations)

Triglyceride Lowering Efficacy

All statins reduce triglycerides effectively, but only in patients with baseline hypertriglyceridemia (>250 mg/dL), with efficacy directly proportional to their LDL-C lowering potency. 6

Key Principles for Triglyceride Reduction:

• Baseline triglyceride level determines response: The triglyceride/LDL-C reduction ratio is approximately 1.2 when baseline TG >250 mg/dL, 0.5 when TG 150-250 mg/dL, and essentially zero when TG <150 mg/dL 6

• More potent statins = greater TG reduction in hypertriglyceridemic patients: Since the TG/LDL-C ratio remains constant across statins, rosuvastatin and high-dose atorvastatin provide the greatest absolute triglyceride lowering in patients with elevated baseline levels 6

• Lovastatin showed highest ranking for TG reduction in one network meta-analysis 3, though this finding should be interpreted cautiously given lovastatin's lower overall potency

Practical Triglyceride Ranking (in hypertriglyceridemic patients):

1. Rosuvastatin 20-40 mg - Highest LDL-C reduction translates to greatest TG lowering
2. Atorvastatin 40-80 mg
3. Other statins in descending order of LDL-C potency

Important caveat: Fibrates and niacin have mild LDL-lowering effects but RCTs do not support their use as add-on therapy to statins for triglyceride management 1.

Clinical Application Algorithm

For maximum lipid lowering (both LDL-C and TG):

• Start with rosuvastatin 20-40 mg (first choice) or atorvastatin 40-80 mg (second choice)
• These are the only statins proven in RCTs to reduce major cardiovascular events at high-intensity doses 1, 5

For moderate lipid lowering or statin intolerance:

• Use rosuvastatin 5-10 mg, atorvastatin 10-20 mg, or simvastatin 20-40 mg

For patients requiring minimal LDL-C reduction:

• Consider pravastatin 10-20 mg, simvastatin 10 mg, or fluvastatin

Critical Safety Considerations

• Simvastatin 80 mg is contraindicated for initiation or up-titration due to increased myopathy/rhabdomyolysis risk 1, 5
• Individual responses vary significantly in clinical practice despite population-level predictions 1
• Asian populations may demonstrate enhanced response to certain statins, requiring dose adjustments 1
• The benefit of statins extends beyond lipid lowering: each 1% LDL-C reduction yields approximately 1% ASCVD risk reduction 2

The evidence overwhelmingly supports rosuvastatin as the most efficacious statin for both LDL-cholesterol and triglyceride reduction when baseline triglycerides are elevated, with atorvastatin as a close second option 3, 7, 4.